RU2017133011A3 - - Google Patents

Download PDF

Info

Publication number
RU2017133011A3
RU2017133011A3 RU2017133011A RU2017133011A RU2017133011A3 RU 2017133011 A3 RU2017133011 A3 RU 2017133011A3 RU 2017133011 A RU2017133011 A RU 2017133011A RU 2017133011 A RU2017133011 A RU 2017133011A RU 2017133011 A3 RU2017133011 A3 RU 2017133011A3
Authority
RU
Russia
Application number
RU2017133011A
Other languages
Russian (ru)
Other versions
RU2764767C2 (ru
RU2017133011A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2017133011A publication Critical patent/RU2017133011A/ru
Publication of RU2017133011A3 publication Critical patent/RU2017133011A3/ru
Application granted granted Critical
Publication of RU2764767C2 publication Critical patent/RU2764767C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/207—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
RU2017133011A 2015-03-06 2016-03-07 β-D-2'-ДЕЗОКСИ-2'-α-ФТОР-2'-β-С-ЗАМЕЩЕННЫЕ-2-МОДИФИЦИРОВАННЫЕ-N6-ЗАМЕЩЕННЫЕ ПУРИНОВЫЕ НУКЛЕОТИДЫ ДЛЯ ЛЕЧЕНИЯ ВЫЗВАННЫХ HCV ЗАБОЛЕВАНИЙ RU2764767C2 (ru)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562129319P 2015-03-06 2015-03-06
US62/129,319 2015-03-06
US201562253958P 2015-11-11 2015-11-11
US62/253,958 2015-11-11
US201662276597P 2016-01-08 2016-01-08
US62/276,597 2016-01-08
PCT/US2016/021276 WO2016144918A1 (en) 2015-03-06 2016-03-07 β-D-2'-DEOXY-2'α-FLUORO-2'-β-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT

Publications (3)

Publication Number Publication Date
RU2017133011A RU2017133011A (ru) 2019-04-09
RU2017133011A3 true RU2017133011A3 (enExample) 2019-09-13
RU2764767C2 RU2764767C2 (ru) 2022-01-21

Family

ID=56850466

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017133011A RU2764767C2 (ru) 2015-03-06 2016-03-07 β-D-2'-ДЕЗОКСИ-2'-α-ФТОР-2'-β-С-ЗАМЕЩЕННЫЕ-2-МОДИФИЦИРОВАННЫЕ-N6-ЗАМЕЩЕННЫЕ ПУРИНОВЫЕ НУКЛЕОТИДЫ ДЛЯ ЛЕЧЕНИЯ ВЫЗВАННЫХ HCV ЗАБОЛЕВАНИЙ

Country Status (29)

Country Link
US (12) US9828410B2 (enExample)
EP (2) EP3265102B1 (enExample)
JP (4) JP6776273B2 (enExample)
KR (2) KR20220025914A (enExample)
CN (2) CN107427530B (enExample)
AU (5) AU2016229966B2 (enExample)
CA (2) CA2978085C (enExample)
CO (1) CO2017010162A2 (enExample)
DK (1) DK3265102T3 (enExample)
EA (1) EA037098B1 (enExample)
ES (1) ES3049645T3 (enExample)
FI (1) FI3265102T3 (enExample)
GE (5) GEP20237502B (enExample)
IL (3) IL302877A (enExample)
LT (1) LT3265102T (enExample)
MX (2) MX2017011386A (enExample)
MY (2) MY190867A (enExample)
NZ (1) NZ773652A (enExample)
PH (1) PH12017501598B1 (enExample)
PT (1) PT3265102T (enExample)
RS (1) RS67412B1 (enExample)
RU (1) RU2764767C2 (enExample)
SA (1) SA517382236B1 (enExample)
SG (1) SG11201706841PA (enExample)
SI (1) SI3265102T1 (enExample)
SM (1) SMT202500392T1 (enExample)
UA (1) UA124966C2 (enExample)
WO (1) WO2016144918A1 (enExample)
ZA (1) ZA201705852B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015017713A1 (en) 2013-08-01 2015-02-05 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
IL302877A (en) 2015-03-06 2023-07-01 Atea Pharmaceuticals Inc Cell-D-2'-deoxy-2'-alpha-fluoro-2'-cell-C-modified-2-different-N6-purine modified nucleotides for the treatment of hepatitis C virus
US10202412B2 (en) 2016-07-08 2019-02-12 Atea Pharmaceuticals, Inc. β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections
MA45925A (fr) * 2016-08-12 2019-06-19 Janssen Biopharma Inc Nucléosides et nucléotides substitués et leurs analogues
KR102456417B1 (ko) 2016-09-07 2022-10-19 아테아 파마슈티컬즈, 인크. Rna 바이러스 치료를 위한 2'-치환된-n6-치환된 퓨린 뉴클레오티드
CN106432327A (zh) * 2016-09-14 2017-02-22 江苏福瑞生物医药有限公司 一种索非布韦关键中间体的制备方法
RS66554B1 (sr) 2017-02-01 2025-03-31 Atea Pharmaceuticals Inc Nukleotid hemi-sulfat so za lečenje virusa hepatitisa c
EP3773753A4 (en) * 2018-04-10 2021-12-22 ATEA Pharmaceuticals, Inc. TREATMENT OF PATIENTS INFECTED WITH THE HEPATITIS C VIRUS WITH CIRRHOSIS
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
WO2021173713A1 (en) 2020-02-27 2021-09-02 Atea Pharmaceuticals, Inc. Highly active compounds against covid-19
WO2022040473A1 (en) * 2020-08-19 2022-02-24 Atea Pharmaceuticals, Inc. Stereoselective manufacture of selected purine phosphoramidates
US12274700B1 (en) 2020-10-30 2025-04-15 Accencio LLC Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors
JP2024504392A (ja) 2021-01-26 2024-01-31 アテア ファーマシューティカルズ， インコーポレイテッド Ａｔ－５２７ヘミ硫酸塩の有利な形態
CN112961198B (zh) * 2021-02-24 2022-03-25 南京欧信医药技术有限公司 一种嘌呤核苷酸中间体的制备方法
CA3174073A1 (en) 2021-06-17 2022-12-17 Atea Pharmaceuticals, Inc. Advantageous anti-hcv combination therapy
TW202348228A (zh) 2022-02-24 2023-12-16 德商艾斯巴赫生物有限公司 病毒組合療法
WO2025014360A1 (en) 2023-07-07 2025-01-16 Erasmus University Medical Center Rotterdam Guanosine nucleotide analogs for use in preventing and/or treating hepatitis e virus infection
WO2025225661A1 (ja) * 2024-04-26 2025-10-30 旭化成株式会社 感光性樹脂組成物、並びにこれを用いた硬化レリーフパターンの製造方法、硬化膜及びポリイミド膜の製造方法

Family Cites Families (236)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US900629A (en) 1906-02-15 1908-10-06 Robert Wettel Combination latch and key lock.
US4924116A (en) 1988-01-19 1990-05-08 Honeywell Inc. Feedback source coupled FET logic
WO1989012321A1 (en) 1988-06-10 1989-12-14 Mobil Solar Energy Corporation An improved method of fabricating contacts for solar cells
ATE114736T1 (de) 1988-07-08 1994-12-15 Famcy Steel Corp Anwendung von einer zweiphasigen eisen-mangan- aluminium-kohlenstofflegierung mit hoher dämpfungsfähigkeit.
WO1990012427A1 (en) 1989-03-30 1990-10-18 Tellio Joseph Grilli Energy monitor for storage cells
ATE115777T1 (de) 1989-04-04 1994-12-15 Koa Oil Co Ltd Luftbatterie.
CA2297294C (en) 1989-05-15 2005-11-08 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Phosphonomethoxymethylpurine/pyrimidine derivatives
US5015790A (en) 1989-12-13 1991-05-14 E. I. Du Pont De Nemours And Company 1,1,2-trifluoro-6-iodo-1-hexene, 1,1,2-trifluoro-1,5-hexadiene, and processes therefore
US5233031A (en) 1991-09-23 1993-08-03 University Of Rochester Phosphoramidate analogs of 2'-deoxyuridine
IT1249732B (it) 1991-11-26 1995-03-09 Angeletti P Ist Richerche Bio Oligonucleotidi antisenso.
US5977061A (en) 1995-04-21 1999-11-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic N6 - substituted nucleotide analagues and their use
US7517858B1 (en) 1995-06-07 2009-04-14 The Regents Of The University Of California Prodrugs of pharmaceuticals with improved bioavailability
CA2266889A1 (en) 1996-10-16 1998-04-23 Guangyi Wang Purine l-nucleosides, analogs and uses thereof
ZA986614B (en) 1997-07-25 1999-01-27 Gilead Sciences Nucleotide analog composition
ATE344271T1 (de) 1998-02-25 2006-11-15 Univ Emory 2'-fluoronukleoside
CN1329500A (zh) 1998-11-30 2002-01-02 诺沃奇梅兹有限公司 含有抗真菌多肽的抗头屑组合物
DE60002986T2 (de) 1999-02-12 2004-05-19 Glaxo Group Ltd., Greenford Phosphoramidat-, mono-, di-, und triphosphatester von (1r, cis)-4-(6-amino-9h-purin-9-yl)-2-cyclopentene-1-methanol als antivirale mittel
IN191496B (enExample) 1999-07-30 2003-12-06 Ranbaxy Lab Ltd
BR0016058A (pt) 1999-12-03 2003-07-15 Univ California San Diego Compostos de fosfonato
BR0110023A (pt) 2000-04-13 2003-12-30 Pharmasset Ltd Derivados de nucleosìdeo 3'-ou-2' substituìdos para tratamento de infecções por vìrus da hepatite
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
IL153020A0 (en) 2000-05-26 2003-06-24 Idenix Cayman Ltd Methods and compositions for treating flaviviruses and pestiviruses
BR0114837A (pt) 2000-10-18 2006-05-09 Pharmasset Ltd nucleosìdeos modificados para tratamento de infecções viróticas e proliferação celular anormal
AU2002228885A1 (en) 2000-10-18 2002-04-29 Pharmasset Inc Simultaneous quantification of nucleic acids in diseased cells
DZ3487A1 (fr) 2001-01-22 2002-07-25 Merck Sharp & Dohme Derives de nucleoside comme inhibiteurs de l'arn polymerase virale d'arn-dependant
US7105499B2 (en) 2001-01-22 2006-09-12 Merck & Co., Inc. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
US8481712B2 (en) 2001-01-22 2013-07-09 Merck Sharp & Dohme Corp. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
GB0112617D0 (en) 2001-05-23 2001-07-18 Hoffmann La Roche Antiviral nucleoside derivatives
GB0114286D0 (en) 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
BR0210594A (pt) 2001-06-22 2005-11-01 Pharmasset Ltd (beta)-d ou (beta)-l-3-halonucleosìdeo
EP1435974A4 (en) 2001-09-28 2006-09-06 Idenix Cayman Ltd METHODS AND COMPOSITIONS FOR THE TREATMENT OF HEPATITIS C VIRUS USING 4 'MODIFIED NUCLEOSIDES
GB2383042A (en) 2001-10-18 2003-06-18 Cipla Ltd Amorphous alendronate sodium
AU2002351077A1 (en) 2001-11-05 2003-05-19 Exiqon A/S Oligonucleotides modified with novel alpha-l-rna analogues
US7388002B2 (en) 2001-11-14 2008-06-17 Biocryst Pharmaceuticals, Inc. Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
KR100978904B1 (ko) 2001-12-14 2010-08-31 파마셋 인코포레이티드 바이러스 감염 치료용 ｎ4-아실사이토신 뉴클레오사이드
AU2002360697B2 (en) 2001-12-20 2009-04-23 Beth Israel Deaconess Medical Center Treatment of EBV and KHSV infection and associated abnormal cellular proliferation
WO2003062256A1 (en) 2002-01-17 2003-07-31 Ribapharm Inc. 2'-beta-modified-6-substituted adenosine analogs and their use as antiviral agents
AU2003217863B9 (en) 2002-02-28 2009-10-29 Biota Scientific Management Pty Ltd Nucleotide mimics and their prodrugs
RU2004135392A (ru) * 2002-05-06 2005-06-27 Дженелэбс Текнолоджиз, Инк. (Us) Производные нуклеозидов для лечения инфекции, вызываемой вирусом гепатита с
EP2799442A1 (en) 2002-06-28 2014-11-05 IDENIX Pharmaceuticals, Inc. Modified 2' and 3' -nucleoside prodrugs for treating flaviridae infections
MXPA04012779A (es) 2002-06-28 2005-08-19 Idenix Cayman Ltd Profarmacos de 2'- y 3'-nucleosido para tratar infecciones por flaviviridae.
CN101172993A (zh) 2002-06-28 2008-05-07 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒感染的2′－c－甲基－3′－o－l－缬氨酸酯核糖呋喃基胞苷
KR20050035194A (ko) 2002-06-28 2005-04-15 이데닉스 (케이만) 리미티드 플라비비리다에 감염 치료용 2'-ｃ-메틸-3'-ｏ-ｌ-발린에스테르 리보푸라노실 사이티딘
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
WO2004009020A2 (en) 2002-07-24 2004-01-29 Merck & Co., Inc. Pyrrolopyrimidine thionucleoside analogs as antivirals
JP2006507235A (ja) 2002-08-01 2006-03-02 フアーマセツト・インコーポレイテツド フラビウイルス科ウイルス感染治療のためのビシクロ［４．２．１］ノナン系を有する化合物
US20040067877A1 (en) 2002-08-01 2004-04-08 Schinazi Raymond F. 2', 3'-Dideoxynucleoside analogues for the treatment or prevention of Flaviviridae infections
AU2003259735A1 (en) 2002-08-08 2004-02-25 Sirna Therapeutics, Inc. Small-mer compositions and methods of use
ES2624353T3 (es) 2002-11-15 2017-07-13 Idenix Pharmaceuticals Llc 2'-Metil nucleósidos en combinación con interferón y mutación de Flaviviridae
TWI294882B (en) 2002-12-09 2008-03-21 Hoffmann La Roche Anhydrous crystalline azido cytosine hemisulfate derivative
AR043006A1 (es) 2003-02-12 2005-07-13 Merck & Co Inc Proceso para preparar ribonucleosidos ramificados
US20050020675A1 (en) 2003-02-21 2005-01-27 Parthasaradhi Reddy Bandi Bicalutamide polymorphs
WO2004091499A2 (en) 2003-04-09 2004-10-28 Neose Technologies, Inc. Intracellular formation of peptide conjugates
US7429565B2 (en) 2003-04-25 2008-09-30 Gilead Sciences, Inc. Antiviral phosphonate analogs
US20040259934A1 (en) 2003-05-01 2004-12-23 Olsen David B. Inhibiting Coronaviridae viral replication and treating Coronaviridae viral infection with nucleoside compounds
US20040229839A1 (en) 2003-05-14 2004-11-18 Biocryst Pharmaceuticals, Inc. Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
EP1656093A2 (en) 2003-05-14 2006-05-17 Idenix (Cayman) Limited Nucleosides for treatment of infection by corona viruses, toga viruses and picorna viruses
WO2004106356A1 (en) 2003-05-27 2004-12-09 Syddansk Universitet Functionalized nucleotide derivatives
FI2604620T4 (fi) * 2003-05-30 2024-09-11 Gilead Pharmasset Llc Modifioituja fluorinoituja nukleosidianalogeja
KR20060026426A (ko) 2003-06-19 2006-03-23 에프. 호프만-라 로슈 아게 4'-아지도 뉴클레오사이드 유도체의 제조 방법
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
ATE478886T1 (de) 2003-07-25 2010-09-15 Idenix Pharmaceuticals Inc Purin nucleoside für die behandlung von durch flavividrae verursachten krankheiten, einschliesslich hepatitis c
DE10335061B4 (de) 2003-07-31 2005-11-17 Wacker-Chemie Gmbh Verfahren zur Herstellung von OH-geschützten [4-(2,6-damino-9H-purin-9-yl)-1,3-dioxolan-2-yl]methanol-Derivaten
JP2007504152A (ja) 2003-08-27 2007-03-01 ビオタ， インコーポレイテッド 治療剤としての新規三環ヌクレオシドまたはヌクレオチド
GB0401088D0 (en) 2004-01-19 2004-02-18 Univ Cardiff Phosphoramidate derivatives
WO2005090370A1 (en) 2004-02-05 2005-09-29 The Regents Of The University Of California Pharmacologically active agents containing esterified phosphonates and methods for use thereof
US20050182252A1 (en) 2004-02-13 2005-08-18 Reddy K. R. Novel 2'-C-methyl nucleoside derivatives
JP5055564B2 (ja) 2004-06-15 2012-10-24 メルク・シャープ・エンド・ドーム・コーポレイション Ｒｎａ依存性ｒｎａウイルスポリメラーゼの阻害剤としてのｃ−プリンヌクレオシド類似体
WO2006002231A1 (en) 2004-06-22 2006-01-05 Biocryst Pharmaceuticals, Inc. Aza nucleosides, preparation thereof and use as inhibitors of rna viral polymerases
CN1972696B (zh) 2004-06-24 2010-08-11 默沙东公司 用于治疗rna依赖性rna病毒感染的核苷氨基磷酸芳基酯
AU2005260057A1 (en) 2004-06-29 2006-01-12 Avery Dennison Corporation Nonwoven-elastomeric laminate with improved bonding between elastomer and nonwoven web
CN101023094B (zh) 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
BRPI0515279A (pt) 2004-09-14 2008-07-15 Pharmasset Inc preparação de ribofuranosil pirimidinas e purinas 2'fluoro-2'-alquil- substituìdas ou outras opcionalmente substituìdas e seus derivados
CN101166750A (zh) 2004-10-29 2008-04-23 拜奥克里斯特制药公司 治疗用呋喃并嘧啶类化合物和噻吩并嘧啶类化合物
CA2589935A1 (en) 2004-12-09 2006-06-15 Regents Of The University Of Minnesota Nucleosides with antiviral and anticancer activity
BRPI0518984A2 (pt) 2004-12-10 2008-12-16 Univ Emory anÁlogos de nucleosÍdeo de ciclobutil substituÍdos em 2' e 3' para tratamento de infecÇÕes virais e proliferaÇço celular anormal
EP1828217A2 (en) 2004-12-16 2007-09-05 Febit Biotech GmbH Polymerase-independent analysis of the sequence of polynucleotides
EP1858889A1 (en) 2005-03-08 2007-11-28 Biota Scientific Management Pty. Ltd. Bicyclic nucleosides and nucleotides as therapeutic agents
GB0505781D0 (en) 2005-03-21 2005-04-27 Univ Cardiff Chemical compounds
WO2006102533A2 (en) 2005-03-23 2006-09-28 Neopharm, Inc. Pharmaceutically active lipid-based formulation of nucleoside-lipid conjugates
US7514410B2 (en) 2005-03-29 2009-04-07 Biocryst Pharmaceuticals, Inc. Hepatitis C therapies
US20090156545A1 (en) 2005-04-01 2009-06-18 Hostetler Karl Y Substituted Phosphate Esters of Nucleoside Phosphonates
WO2006121820A1 (en) 2005-05-05 2006-11-16 Valeant Research & Development Phosphoramidate prodrugs for treatment of viral infection
EP1915054A4 (en) 2005-08-09 2010-09-01 Merck Sharp & Dohme CYCLIC ACETAL DERIVATIVES OF RIBONUCLEOSIDES FOR THE TREATMENT OF RNA-DEPENDENT RNA VIRUS INFECTIONS
JP2009504677A (ja) 2005-08-12 2009-02-05 メルク・エンド・カムパニー・インコーポレーテツド 新規２’−ｃ−メチル及び４’−ｃ−メチルヌクレオシド誘導体
WO2007020193A2 (en) 2005-08-15 2007-02-22 F. Hoffmann-La Roche Ag Antiviral phosphoramidates of 4 ' -substituted pronucleotides
WO2007056596A2 (en) 2005-11-09 2007-05-18 Wayne State University Phosphoramidate derivatives of fau
US7879815B2 (en) 2006-02-14 2011-02-01 Merck Sharp & Dohme Corp. Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection
US8895531B2 (en) 2006-03-23 2014-11-25 Rfs Pharma Llc 2′-fluoronucleoside phosphonates as antiviral agents
ES2600792T3 (es) 2006-05-03 2017-02-10 Chimerix, Inc. Alcoxialquilésteres metabólicamente estables de fosfonatos, fosfonatos nucleosídicos y fosfatos nucleosídicos antivirales o antiproliferativos
WO2008005542A2 (en) 2006-07-07 2008-01-10 Gilead Sciences, Inc., Antiviral phosphinate compounds
GB0614947D0 (en) 2006-07-27 2006-09-06 Isis Innovation Epitope reduction therapy
RU2421461C2 (ru) 2006-10-10 2011-06-20 Фармассет, Инк. Способ получения рибофуранозил-пиримидиновых нуклеозидов
PL216525B1 (pl) 2006-10-17 2014-04-30 Ct Badań Molekularnych I Makromolekularnych Polskiej Akademii Nauk 5'-O-[(N-acylo)amidoditiofosforano] nukleozydy oraz sposób wytwarzania 5'-O-[(N-acylo)amidofosforano]-,5'-O-[(N-acylo)amidotiofosforano]-, 5'-O-[(N-acylo)amidoditiofosforano]nukleozydów
GB0623493D0 (en) 2006-11-24 2007-01-03 Univ Cardiff Chemical compounds
US8148349B2 (en) 2006-12-20 2012-04-03 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Nucleoside cyclic phosphoramidates for the treatment of RNA-dependent RNA viral infection
US7951789B2 (en) 2006-12-28 2011-05-31 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
WO2008085508A2 (en) 2007-01-05 2008-07-17 Merck & Co., Inc. Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
DK2114980T3 (da) 2007-01-12 2012-09-24 Biocryst Pharm Inc Antivirale nukleosidanaloger
KR20100014878A (ko) 2007-01-31 2010-02-11 앨리오스 바이오파마 인크. 2-5ａ 유도체, 및 항암제, 항바이러스제 및 항기생충제로서 이의 용도
US8324179B2 (en) 2007-02-09 2012-12-04 Gilead Sciences, Inc. Nucleoside analogs for antiviral treatment
US7964580B2 (en) * 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
ES2393038T3 (es) 2007-05-10 2012-12-18 Biocryst Pharmaceuticals, Inc. Compuestos de tretrahidrofuro[3,4-D]dioxolano para su utlilización en el tratamiento de las infecciones víricas y del cáncer
US20100279969A1 (en) 2007-05-14 2010-11-04 Rfs Pharma, Llc Azido purine nucleosides for treatment of viral infections
SI2014771T1 (sl) 2007-06-25 2015-04-30 Anadys Pharmaceuticals, Inc. Kontinuiran postopek encimske hidrolize
GB0712494D0 (en) 2007-06-27 2007-08-08 Isis Innovation Substrate reduction therapy
US20090060867A1 (en) 2007-08-31 2009-03-05 Idenix Pharmaceuticals, Inc. Phosphadiazine hcv polymerase inhibitors iii and vi
US20090318380A1 (en) 2007-11-20 2009-12-24 Pharmasset, Inc. 2',4'-substituted nucleosides as antiviral agents
WO2009086192A1 (en) 2007-12-21 2009-07-09 Alios Biopharma, Inc. Biodegradable phosphate protected nucleotide derivatives and their use as cancer, anti viral and anti parasitic agents
US20090181921A1 (en) 2007-12-21 2009-07-16 Alios Biopharma Inc. 2-5a analogs and their methods of use
TW200942243A (en) 2008-03-05 2009-10-16 Biocryst Pharm Inc Antiviral therapeutic agents
EP2268288A4 (en) 2008-04-15 2012-05-30 Rfs Pharma Llc NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF CALICIVIRIDAE INFECTIONS, INCLUDING NOROVIRUS INFECTIONS
HRP20150359T1 (hr) 2008-04-23 2015-05-22 Gilead Sciences, Inc. 1'-supstituirani karba-nukleozidni analozi za antivirusnu terapiju
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
UY31950A (es) 2008-07-01 2010-01-29 Medivir Ab Inhibidores de ciclopropil-polimerasa
EP2313102A2 (en) 2008-07-03 2011-04-27 Biota Scientific Management Bycyclic nucleosides and nucleotides as therapeutic agents
EP2326626B1 (en) 2008-08-20 2013-10-16 Merck Sharp & Dohme Corp. Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
AU2009282572B2 (en) 2008-08-20 2014-09-11 Merck Sharp & Dohme Corp. Azo-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
AR072940A1 (es) 2008-08-20 2010-09-29 Schering Corp Derivados de piridina y pirimidina sustituidos con etinilo y su uso en el tratamiento de infecciones virales
TWI409265B (zh) 2008-08-20 2013-09-21 Merck Sharp & Dohme 經取代之吡啶及嘧啶衍生物及彼等於治療病毒感染之用途
PA8852101A1 (es) 2008-12-08 2010-07-27 Medivir Ab Nucleótidos uracil ciclopropílicos
WO2010068708A2 (en) 2008-12-09 2010-06-17 Rfs Pharma, Llc 3'-azido purine nucleotide prodrugs for treatment of viral infections
CN102753563A (zh) 2008-12-23 2012-10-24 吉利德制药有限责任公司 核苷类似物
AR074977A1 (es) 2008-12-23 2011-03-02 Pharmasset Inc Sintesis de nucleosidos de purina
US8716262B2 (en) * 2008-12-23 2014-05-06 Gilead Pharmasset Llc Nucleoside phosphoramidates
MX2011007364A (es) 2009-01-09 2012-02-28 Univ Cardiff Derivados de fosforamidato de compuestos de nuecleosido de guanosina para tratamiento de infecciones virales.
JP2012517443A (ja) * 2009-02-06 2012-08-02 アールエフエス ファーマ，エルエルシー 癌及びウイルス感染の治療のためのプリンヌクレオシド一リン酸プロドラッグ
CN102348713B (zh) 2009-02-10 2015-12-02 吉里德科学公司 用于抗病毒治疗的carba-核苷类似物
AR075584A1 (es) 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
WO2010101967A2 (en) 2009-03-04 2010-09-10 Idenix Pharmaceuticals, Inc. Phosphothiophene and phosphothiazole hcv polymerase inhibitors
EA201190178A1 (ru) 2009-03-20 2012-06-29 Алиос Биофарма, Инк. Замещённые нуклеозидные и нуклеотидные аналоги
US20100240604A1 (en) 2009-03-20 2010-09-23 Alios Biopharma, Inc. Protected nucleotide analogs
JO3027B1 (ar) 2009-05-14 2016-09-05 Janssen Products Lp نيوكليوسيدات يوراسيل سبيرواوكسيتان
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
EP2264169A1 (en) 2009-06-15 2010-12-22 Qiagen GmbH Modified siNA
WO2011005595A2 (en) 2009-06-24 2011-01-13 Alios Biopharma, Inc. 2-5a analogs and their methods of use
US8927513B2 (en) 2009-07-07 2015-01-06 Alnylam Pharmaceuticals, Inc. 5′ phosphate mimics
US7973013B2 (en) 2009-09-21 2011-07-05 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
US8455451B2 (en) 2009-09-21 2013-06-04 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
EP2483288B1 (en) 2009-09-29 2016-11-16 Janssen Products, L.P. Phosphoramidate derivatives of nucleosides
US8816074B2 (en) 2009-11-16 2014-08-26 University of Georgia Foundation, Inc. 2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections
WO2011060408A2 (en) 2009-11-16 2011-05-19 University Of Georgia Research Foundation, Inc. 2'-fluoro-6'-methylene carbocyclic nucleosides and methods of treating viral infections
CN102822175A (zh) 2009-12-18 2012-12-12 埃迪尼克斯医药公司 5,5-稠合的亚芳基或亚杂芳基丙型肝炎病毒抑制剂
US8333309B2 (en) 2010-03-02 2012-12-18 Kenneth Riddleberger Hunter's adjustable encapsulating scent adsorption system with combination pack and detachably securable flexible funnel for human odor adsorption
PT3290428T (pt) 2010-03-31 2021-12-27 Gilead Pharmasset Llc Comprimido compreendendo 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihidropirimidin-1-(2h)-il)¿4¿fluoro¿3¿hidroxi¿4¿metiltetrahidrofuran¿2¿il)metoxi) (fenoxi)fosforil)amino)propanoato de (s)- isopropil cristalino
US8563530B2 (en) * 2010-03-31 2013-10-22 Gilead Pharmassel LLC Purine nucleoside phosphoramidate
TWI515000B (zh) 2010-04-01 2016-01-01 伊迪尼克製藥公司 用於治療病毒感染之化合物及醫藥組合物
EP2558466A4 (en) 2010-04-14 2013-11-13 Univ California PHOSPHONATES WITH REDUCED TOXICITY FOR THE TREATMENT OF VIRUS INFECTIONS
TW201201815A (en) 2010-05-28 2012-01-16 Gilead Sciences Inc 1'-substituted-carba-nucleoside prodrugs for antiviral treatment
ES2524398T3 (es) 2010-07-19 2014-12-09 Gilead Sciences, Inc. Métodos para la preparación de profármacos de fosforoamidato diastereoméricamente puros
EP2616461A4 (en) 2010-08-26 2014-03-26 Rfs Pharma Llc POTENTIVE AND SELECTIVE INHIBITORS OF HEPATITIS C VIRUS
WO2012040126A1 (en) 2010-09-22 2012-03-29 Alios Biopharma, Inc. Substituted nucleotide analogs
JP6012605B2 (ja) 2010-09-22 2016-10-25 アリオス バイオファーマ インク． 置換されたヌクレオチドアナログ
WO2012040124A1 (en) 2010-09-22 2012-03-29 Alios Biopharma, Inc. Azido nucleosides and nucleotide analogs
WO2012041965A1 (en) 2010-09-29 2012-04-05 Universidad Nacional De Quilmes Process for producing dialkylphosphotriesters of nucleosides by enzymatic transesterification and deprotection thereof for producing nucleoside monophosphates
WO2012048013A2 (en) 2010-10-06 2012-04-12 Inhibitex, Inc. Phosphorodiamidate derivatives of guanosine nucleoside compounds for treatment of viral injections
US9012428B2 (en) 2010-11-10 2015-04-21 Janssen Products, Lp Uracyl spirooxetane nucleoside phosphoramidates
US8841275B2 (en) 2010-11-30 2014-09-23 Gilead Pharmasset Llc 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections
JP5891241B2 (ja) * 2010-12-20 2016-03-22 ギリアード サイエンシーズ， インコーポレイテッド Ｈｃｖを処置するための組合せ
EP2655392B1 (en) * 2010-12-22 2018-04-18 Alios Biopharma, Inc. Cyclic nucleotide analogs
EP2658857B1 (en) 2010-12-29 2016-11-02 Inhibitex, Inc. Substituted purine nucleosides, phosphoroamidate and phosphorodiamidate derivatives for treatment of viral infections
WO2012094248A1 (en) 2011-01-03 2012-07-12 Nanjing Molecular Research, Inc. O-(substituted benzyl) phosphoramidate compounds and therapeutic use
CA2828326C (en) 2011-03-01 2019-05-07 Nucana Biomed Limited Phosphoramidate derivatives of 5 - fluoro - 2' - deoxyuridine for use in the treatment of cancer
US9085599B2 (en) 2011-03-16 2015-07-21 Enanta Pharmaceuticals, Inc. 2′allene-substituted nucleoside derivatives
CN103842369A (zh) 2011-03-31 2014-06-04 埃迪尼克斯医药公司 用于治疗病毒感染的化合物和药物组合物
WO2012142075A1 (en) 2011-04-13 2012-10-18 Merck Sharp & Dohme Corp. 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
JP2014515023A (ja) 2011-04-13 2014-06-26 メルク・シャープ・アンド・ドーム・コーポレーション ２’−置換ヌクレオシド誘導体およびウイルス疾患の処置のためのその使用方法
JP6043338B2 (ja) 2011-04-13 2016-12-14 ギリアード サイエンシーズ， インコーポレイテッド 抗ウイルス治療用の１’−置換ピリミジンｎ−ヌクレオシド類似体
US20140212382A1 (en) 2011-05-19 2014-07-31 Emory University Purine monophosphate prodrugs for treatment of viral infections
EP2731433A4 (en) 2011-07-13 2014-12-31 Merck Sharp & Dohme 5'-SUBSTITUTED NUCLEOSIDE ANALOGA AND METHOD FOR THEIR USE FOR THE TREATMENT OF VIRUS DISEASES
US9334300B2 (en) 2011-08-01 2016-05-10 Mbc Pharma, Inc. Vitamin B6 derivatives of nucleotides, acyclonucleotides and acyclonucleoside phosphonates
AU2012308900A1 (en) 2011-09-12 2013-05-09 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
US9403863B2 (en) 2011-09-12 2016-08-02 Idenix Pharmaceuticals Llc Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
WO2013044030A1 (en) 2011-09-23 2013-03-28 Enanta Pharmaceuticals, Inc. 2'-chloroacetylenyl substituted nucleoside derivatives
TW201331221A (zh) 2011-10-14 2013-08-01 Idenix Pharmaceuticals Inc 嘌呤核苷酸化合物類之經取代的３’，５’－環磷酸酯及用於治療病毒感染之醫藥組成物
BR112014009634A2 (pt) 2011-10-19 2017-05-09 Mercator Medsystems Inc preparação e agente terapêutico
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
WO2013090420A2 (en) 2011-12-12 2013-06-20 Catabasis Pharmaceuticals, Inc. Fatty acid antiviral conjugates and their uses
GB2497580A (en) 2011-12-16 2013-06-19 Intercede Ltd Data transmission using a plurality of barcodes displayed in a loop
WO2013096680A1 (en) 2011-12-22 2013-06-27 Alios Biopharma, Inc. Substituted phosphorothioate nucleotide analogs
US8673926B2 (en) 2012-02-14 2014-03-18 University Of Georgia Research Foundation, Inc. Spiro[2.4]heptanes for treatment of flaviviridae infections
EP2820016B1 (en) 2012-02-27 2017-08-02 Bristol-Myers Squibb Company N- (5s, 6s, 9r) - 5 -amino- 6 - (2, 3 - difluorophenyl) -6, 7, 8, 9 - tetrahydro - 5h - cyclohepta [b]pyridin-9 -yl- 4 - (2 - oxo-2, 3 - dihydro - 1h- imidazo [4, 5 -b]pyridin - 1 - yl) piperidine - 1 - carboxylate, hemisulfate salt
WO2013142159A1 (en) 2012-03-21 2013-09-26 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
WO2013142125A1 (en) 2012-03-21 2013-09-26 Alios Biopharma, Inc. Methods of preparing substituted nucleotide analogs
EP2827876A4 (en) 2012-03-22 2015-10-28 Alios Biopharma Inc PHARMACEUTICAL COMBINATIONS WITH A THIONUCLEOTIDE ANALOG
WO2013151975A1 (en) 2012-04-02 2013-10-10 Northeastern University Compositions and methods for the inhibition of methyltransferases
CN102659843B (zh) * 2012-04-24 2015-06-24 北京大学 D,l-鸟嘌呤核苷类似物单磷酸酯及其制备方法和应用
WO2013173759A2 (en) 2012-05-17 2013-11-21 Enanta Pharmaceuticals, Inc. Macrocyclic nucleoside phosphoramidate derivatives
EP2852604B1 (en) 2012-05-22 2017-04-12 Idenix Pharmaceuticals LLC 3',5'-cyclic phosphoramidate prodrugs for hcv infection
HK1203514A1 (en) 2012-05-22 2015-10-30 Idenix Pharmaceuticals Llc D-amino acid compounds for liver disease
CN104640444B (zh) 2012-06-16 2016-12-14 河南美泰宝生物制药有限公司 双肝脏靶向氨基磷酸酯和氨基膦酸酯前药
CN104583224A (zh) 2012-07-03 2015-04-29 百时美施贵宝公司 制备用于治疗病毒感染的核苷化合物的富含非对映体的氨基磷酸酯衍生物的方法
WO2014047117A1 (en) 2012-09-18 2014-03-27 Bristol-Myers Squibb Company Process for preparing phosphoramidate derivatives of nucleoside compounds for treatment of viral infections
WO2014052638A1 (en) 2012-09-27 2014-04-03 Idenix Pharmaceuticals, Inc. Esters and malonates of sate prodrugs
CN104936970A (zh) 2012-10-08 2015-09-23 埃迪尼克斯医药公司 用于hcv感染的2′-氯核苷类似物
EP2909223B1 (en) 2012-10-19 2017-03-22 Idenix Pharmaceuticals LLC Dinucleotide compounds for hcv infection
JP2015535261A (ja) 2012-10-29 2015-12-10 コクリスタル ファーマ，インコーポレイテッド ウイルス感染及び癌の治療のためのピリミジンヌクレオチド及びその一リン酸プロドラッグ
US10005810B2 (en) 2012-11-16 2018-06-26 University College Cardiff Consultants Limited Process for preparing nucleoside prodrugs
GB201220843D0 (en) 2012-11-20 2013-01-02 Univ College Cork Nat Univ Ie Compound
US20140205566A1 (en) * 2012-11-30 2014-07-24 Novartis Ag Cyclic nucleuoside derivatives and uses thereof
WO2014099941A1 (en) 2012-12-19 2014-06-26 Idenix Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
KR102532198B1 (ko) 2012-12-21 2023-05-11 얀센 바이오파마, 인코퍼레이트. 치환된 뉴클레오사이드, 뉴클레오타이드 및 그것의 유사체
WO2014100498A1 (en) 2012-12-21 2014-06-26 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
HUE047777T2 (hu) 2013-01-31 2020-05-28 Gilead Pharmasset Llc Két vírusellenes vegyület kombinációs készítménye
WO2014124430A1 (en) 2013-02-11 2014-08-14 Emory University Nucleotide and nucleoside therapeutic compositions and uses related thereto
WO2014137930A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. Thiophosphate nucleosides for the treatment of hcv
WO2014165542A1 (en) 2013-04-01 2014-10-09 Idenix Pharmaceuticals, Inc. 2',4'-fluoro nucleosides for the treatment of hcv
BR112015025716A2 (pt) 2013-04-12 2017-07-18 Achillion Pharmaceuticals Inc pró-fármacos de nucleosídeo submetidos a deutério úteis para o tratamento de hcv
CN103435672A (zh) 2013-04-25 2013-12-11 刘沛 含有取代苄基的新型核苷磷酸酯前药的结构与合成
TW201542578A (zh) 2013-06-26 2015-11-16 Alios Biopharma Inc 經取代之核苷、核苷酸及其類似物
CA2916912A1 (en) 2013-07-02 2015-01-08 Abbvie Inc. Methods for treating hcv
PL3043803T3 (pl) 2013-09-11 2022-11-07 Emory University Kompozycje nukleotydowe i nukleozydowe oraz ich zastosowanie
TW201524990A (zh) 2013-10-11 2015-07-01 Alios Biopharma Inc 經取代之核苷、核苷酸及其類似物
US8889701B1 (en) 2013-10-11 2014-11-18 Alla Chem, Llc Substituted (S)-(2R,3R,5R)-3-hydroxy-(5-pyrimidin-1-yl)tetrahydrofuran-2-ylmethyl aryl phosphoramidate
WO2015061683A1 (en) 2013-10-25 2015-04-30 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv
EP3063165A1 (en) 2013-11-01 2016-09-07 Idenix Pharmaceuticals LLC D-alanine phosphoramidate pronucleotides of 2'-methyl 2'-fluoro guanosine nucleoside compounds for the treatment of hcv
CN104211748B (zh) * 2013-11-15 2017-05-31 南京济群医药科技股份有限公司 6‑羟基双脱氧鸟嘌呤核苷磷酸酯制备和用途
BR112016011949A8 (pt) 2013-11-27 2020-04-28 Idenix Pharmaceuticals Llc composto, composição farmacêutica, e, uso dos mesmos”
US20150150897A1 (en) 2013-12-02 2015-06-04 Gilead Pharmasset Llc Methods of treating hepatitis c virus infection in subjects with cirrhosis
WO2015095305A1 (en) 2013-12-17 2015-06-25 Idenix Pharmaceuticals, Inc. Production of cyclic phosphate, phosphoramidate, thiophosphate, and phosphonate nucleoside compounds
US20170022242A1 (en) 2014-04-17 2017-01-26 Katholieke Universiteit Leuven, KU LEUVEN R&D Novel antiviral and antitumoral compounds
SG11201610599TA (en) 2014-06-24 2017-01-27 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
JP6669675B2 (ja) 2014-06-24 2020-03-18 ヤンセン バイオファーマ インク． 置換ヌクレオシド、ヌクレオチドおよびその類似体
US10118941B2 (en) 2014-09-15 2018-11-06 Medivir Ab Methods for the preparation of diastereomerically pure phosphoramidate prodrugs
CN105646629A (zh) 2014-11-25 2016-06-08 广州市恒诺康医药科技有限公司 L-核苷类化合物及其应用
MA41213A (fr) 2014-12-19 2017-10-24 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
MA41441A (fr) 2014-12-19 2017-12-12 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
IL302877A (en) 2015-03-06 2023-07-01 Atea Pharmaceuticals Inc Cell-D-2'-deoxy-2'-alpha-fluoro-2'-cell-C-modified-2-different-N6-purine modified nucleotides for the treatment of hepatitis C virus
WO2016145142A1 (en) 2015-03-10 2016-09-15 Emory University Nucleotide and nucleoside therapeutics compositions and uses related thereto
CN106188192B (zh) 2015-04-29 2019-09-10 刘沛 含d-氨基酸酯的核苷氨基磷酸/膦酸酯衍生物及其医药用途
US10202412B2 (en) 2016-07-08 2019-02-12 Atea Pharmaceuticals, Inc. β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections
LU100724B1 (en) 2016-07-14 2018-07-31 Atea Pharmaceuticals Inc Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
KR102456417B1 (ko) 2016-09-07 2022-10-19 아테아 파마슈티컬즈, 인크. Rna 바이러스 치료를 위한 2'-치환된-n6-치환된 퓨린 뉴클레오티드
RS66554B1 (sr) 2017-02-01 2025-03-31 Atea Pharmaceuticals Inc Nukleotid hemi-sulfat so za lečenje virusa hepatitisa c
EP3773753A4 (en) 2018-04-10 2021-12-22 ATEA Pharmaceuticals, Inc. TREATMENT OF PATIENTS INFECTED WITH THE HEPATITIS C VIRUS WITH CIRRHOSIS

Also Published As

Publication number Publication date
AU2016229966A8 (en) 2017-10-12
PH12017501598B1 (en) 2023-07-05
US20240002426A1 (en) 2024-01-04
LT3265102T (lt) 2025-10-27
MX2017011386A (es) 2018-04-26
GEP20247600B (en) 2024-02-26
EA201791903A1 (ru) 2018-01-31
RU2764767C2 (ru) 2022-01-21
NZ734908A (en) 2021-10-29
US20200308215A1 (en) 2020-10-01
IL254111A0 (en) 2017-10-31
SMT202500392T1 (it) 2025-11-10
IL302877A (en) 2023-07-01
US9828410B2 (en) 2017-11-28
EP3265102B1 (en) 2025-08-20
AU2018282469B2 (en) 2020-02-13
CA2978085C (en) 2023-01-17
CO2017010162A2 (es) 2018-01-05
IL295418B2 (en) 2023-10-01
GEAP202215528A (en) 2022-11-10
HK1247829A1 (en) 2018-10-05
US10239911B2 (en) 2019-03-26
CN107427530A (zh) 2017-12-01
RU2017133011A (ru) 2019-04-09
RS67412B1 (sr) 2025-12-31
US20220267366A1 (en) 2022-08-25
CN107427530B (zh) 2020-09-08
JP2018507261A (ja) 2018-03-15
AU2016229966A1 (en) 2017-09-14
AU2016229966B2 (en) 2018-09-27
ES3049645T3 (en) 2025-12-17
US20250243235A1 (en) 2025-07-31
CN112209980B (zh) 2023-12-05
US20180030081A1 (en) 2018-02-01
EA037098B1 (ru) 2021-02-05
GEP20237502B (en) 2023-04-25
US20190177356A1 (en) 2019-06-13
KR102363946B1 (ko) 2022-02-17
BR112017018977A2 (pt) 2018-05-22
MX2022015612A (es) 2023-02-13
SG11201706841PA (en) 2017-09-28
AU2018282469A1 (en) 2019-01-24
MY201444A (en) 2024-02-22
MY190867A (en) 2022-05-13
EP3265102A4 (en) 2018-12-05
AU2020203055B2 (en) 2021-03-25
US20160257706A1 (en) 2016-09-08
JP6776273B2 (ja) 2020-10-28
US10870673B2 (en) 2020-12-22
AU2020203055A1 (en) 2020-05-28
US12084473B2 (en) 2024-09-10
PT3265102T (pt) 2025-10-30
NZ773652A (en) 2024-08-30
UA124966C2 (uk) 2021-12-22
CN112209980A (zh) 2021-01-12
JP7532440B2 (ja) 2024-08-13
US20200331955A1 (en) 2020-10-22
IL295418A (en) 2022-10-01
PH12017501598A1 (en) 2018-02-12
FI3265102T3 (fi) 2025-10-31
CA3182565A1 (en) 2016-09-15
US10870672B2 (en) 2020-12-22
US20180282364A1 (en) 2018-10-04
US10005811B2 (en) 2018-06-26
US10000523B2 (en) 2018-06-19
AU2021204022B2 (en) 2023-05-18
JP7053754B2 (ja) 2022-04-12
JP2024160265A (ja) 2024-11-13
KR20170120700A (ko) 2017-10-31
JP2021008494A (ja) 2021-01-28
WO2016144918A1 (en) 2016-09-15
SA517382236B1 (ar) 2022-09-07
AU2023202634A1 (en) 2023-05-18
IL254111B (en) 2021-04-29
JP2022088596A (ja) 2022-06-14
EP3265102A1 (en) 2018-01-10
US20200331956A1 (en) 2020-10-22
US20210009628A1 (en) 2021-01-14
GEP20217282B (en) 2021-08-10
EP4667053A2 (en) 2025-12-24
IL295418B1 (en) 2023-06-01
ZA201705852B (en) 2019-11-27
US20180030082A1 (en) 2018-02-01
US10875885B2 (en) 2020-12-29
KR20220025914A (ko) 2022-03-03
AU2021204022A1 (en) 2021-07-08
SI3265102T1 (sl) 2025-11-28
DK3265102T3 (da) 2025-10-13
US10815266B2 (en) 2020-10-27
GEAP202114600A (en) 2021-04-12
CA2978085A1 (en) 2016-09-15

Similar Documents

Publication Publication Date Title
BE2015C047I2 (enExample)
CN303071550S (enExample)
BR0002402B1 (enExample)
BR0000126B1 (enExample)
BR0000695B1 (enExample)
BR0000763F1 (enExample)
BR0001536B1 (enExample)
BR0001684B1 (enExample)
BR0001810B1 (enExample)
BR0002033B1 (enExample)
CN303071700S (enExample)
BR0002435B1 (enExample)
BR0002694B1 (enExample)
BR0002802B1 (enExample)
BR0002874B1 (enExample)
BR0003166B1 (enExample)
BR0003189B1 (enExample)
BR0003208B1 (enExample)
BR0003401B1 (enExample)
BR0003686B1 (enExample)
BR0003746B1 (enExample)
BR0003751B1 (enExample)
BR0003928B1 (enExample)
BR0004687B1 (enExample)
BR0005041B1 (enExample)